Hubbry Logo
XISTXISTMain
Open search
XIST
Community hub
XIST
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
XIST
XIST
XIST
View on Wikipedia
from Wikipedia

XIST
Identifiers
AliasesXIST, DXS1089, DXS399E, LINC00001, NCRNA00001, SXI1, swd66, X inactive specific transcript (non-protein coding), X inactive specific transcript, Xist
External IDsOMIM: 314670; MGI: 98974; GeneCards: XIST; OMA:XIST - orthologs
Orthologs
SpeciesHumanMouse
Entrez

7503

213742

Ensembl

ENSG00000229807

ENSMUSG00000086503

UniProt

n
a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)Chr X: 73.82 – 73.85 MbChr X: 102.5 – 102.53 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Xist (X-inactive specific transcript) is a non-coding RNA transcribed from the X chromosome of the placental mammals that acts as a major effector of the X-inactivation process.[5] It is a component of the Xic – X-chromosome inactivation centre[6] – along with two other RNA genes (Jpx and Ftx) and two protein genes (Tsx and Cnbp2).[7]

The Xist RNA, a large (17 kb in humans)[8] transcript, is expressed on the inactive chromosome and not on the active one. It is processed in a similar way to mRNAs, through splicing and polyadenylation. However, it remains untranslated. It has been suggested that this RNA gene evolved at least partly from a protein-coding gene that became a pseudogene.[9] The inactive X chromosome is coated with this transcript, which is essential for the inactivation.[10] X chromosomes lacking Xist will not be inactivated, while duplication of the Xist gene on another chromosome causes inactivation of that chromosome.[11]

The human Xist gene was discovered by Andrea Ballabio through a cDNA library screening and then characterized in collaboration with Carolyn J. Brown and Hunt Willard.[12][13]

Function

[edit]

X-inactivation is an early developmental process in mammalian females that transcriptionally silences one of the pair of X chromosomes, thus providing dosage equivalence between males and females (see dosage compensation). The process is regulated by several factors, including a region of chromosome X called the X-inactivation center (XIC). The XIST gene is expressed exclusively from the XIC of the inactive X chromosome. The transcript is spliced but apparently does not encode a protein. The transcript remains in the nucleus where it coats the inactive X chromosome. Alternatively spliced transcript variants have been identified, but their full length sequences have not been determined.[5]

The functional role of the Xist transcript was definitively demonstrated in mouse female ES cells using a novel antisense technology, called peptide nucleic acid (PNA) interference mapping. In the reported experiments, a single 19-bp antisense cell-permeating PNA targeted against a particular region of Xist RNA prevented the formation of Xi and inhibited cis-silencing of X-linked genes. The association of the Xi with macro-histone H2A is also disturbed by PNA interference mapping.[14] The X-inactivation process occurs in mice even in the absence of this gene via epigenetic regulation, but Xist is required to stabilize this silencing.[15]

In addition to being expressed in nearly all females, XIST is expressed in narrow developmental contexts in males including human preimplantation embryos, primordial germ cells, testicular germ cell tumors, and a subset of male cancers of diverse lineages.[16] It may be involved in the dosage compensation of supernumerary X chromosomes in the latter two cases.

Gene location

[edit]

The human Xist RNA gene is located on the long (q) arm of the X chromosome. The Xist RNA gene contains conserved repeats within its structure. Its gene product is largely localized in the nucleus.[8] The Xist RNA gene features a conserved A region, which contains 8 repeats separated by U-rich spacers. The A region appears to encode two long stem-loop RNA structures that each include four repeats.[17] An ortholog of the Xist RNA gene in humans has been identified in mice.[18][19] This ortholog encodes a 15 kb Xist transcript that is also localized in the nucleus. However, the ortholog does not feature conserved repeats.[20] The Xist RNA gene is located within the Xist Inactivation Center (XIC), which plays a major role in X-inactivation.[21]

Transcript organization

[edit]

A region

[edit]
Structure model of the repeat A (repA) region of Xist based on in vivo biochemical structure probing and comparative sequence analysis. Repeats 1 to 8(1/2) are numbered and boxed - they are shown in red on the cartoon of repA in the upper left hand panel. Reactive nucleotides are colored red, where open and closed circles are medium and strongly reactive, respectively (reactivity suggests that a nucleotide is unpaired or loosely structured). Consistent and compensatory mutations (single and double point mutations that preserve pairing) are annotated in blue and purple, respectively. Base pairs that are 100% conserved in rodents are bold and black, while those conserved in rodents and mammals are in green. The data and model are taken from Fang R, Moss WN, Rutenberg-Schoenberg M, Simon MD (December 2015). "Probing Xist RNA Structure in Cells Using Targeted Structure-Seq". PLOS Genetics. 11 (12) e1005668. doi:10.1371/journal.pgen.1005668. PMC 4672913. PMID 26646615..

The Xist RNA contains a region of conservation called the repeat A (repA) region that contains up to nine repeated elements.[17] It was initially suggested that repA repeats could fold back on themselves to form local intra-repeat stem-loop structures. Later work using in vitro biochemical structure probing proposed several inter-repeat stem-loop structures.[8][17] A recent study using in vivo biochemical probing and comparative sequence analysis proposed a revision of the repA structure model that includes both intra-repeat and inter-repeat folding found in previous models as well as novel features (see Figure). In addition to its agreement with the in vivo data, this revised model is highly conserved in rodents and mammals (including humans) suggesting functional importance for repA structure. Although the exact function of the repA region is uncertain, it was shown that the entire region is needed for efficient binding to the Suz12 protein.[17]

C region

[edit]

The Xist RNA directly binds to the inactive X-chromosome through a chromatin binding region of the RNA transcript. The Xist chromatin binding region was first elucidated in female mouse fibroblastic cells. The primary chromatin binding region was shown to localize to the C-repeat region. The chromatin-binding region was functionally mapped and evaluated by using an approach for studying noncoding RNA function in living cells called peptide nucleic acid (PNA) interference mapping. In the reported experiments, a single 19-bp antisense cell-permeating PNA targeted against a particular region of Xist RNA caused the disruption of the Xi. The association of the Xi with macro-histone H2A is also disturbed by PNA interference mapping.[14]

X-inactivation centre (XIC)

[edit]

The Xist RNA gene lies within the X-inactivation centre (XIC), which plays a major role in Xist expression and X-inactivation.[22] The XIC is located on the q arm of the X chromosome (Xq13). XIC regulates Xist in cis X-inactivation, where Tsix, an antisense of Xist, downregulates the expression of Xist. The Xist promoter of XIC is the master regulator of X-inactivation.[21] X-inactivation plays a key role in dosage compensation.

Tsix antisense transcript

[edit]

The Tsix antisense gene is a transcript of the Xist gene at the XIC center.[23] The Tsix antisense transcript acts in cis to repress the transcription of Xist, which negatively regulates its expression. The mechanism behind how Tsix modulates Xist activity in cis is poorly understood; however, there are a few theories on its mechanism. One theory is that Tsix is involved in chromatin modification at the Xist locus and another is that transcription factors of pluripotent cells play a role in Xist repression.[24]

Regulation of the Xist promoter

[edit]

Methylation

[edit]

The Tsix antisense is believed to activate DNA methyl transferases that methylate the Xist promoter, in return resulting in inhibition of the Xist promoter and thus the expression of the Xist gene.[25] In contrast to Tsix acting, which is an inhibitor to Xist, the methylation of histone 3 lysine 4 (H3K4) up regulates the transcription by opening the chromatin structure. The open chromatin enables the recruitment of transcription factors and thus allows for transcription to occur.[26]

dsRNA and RNAi

[edit]

A dsRNA and RNAi pathway have been also proposed to play a role in regulation of the Xist Promoter. Dicer is an RNAi enzyme and it is believed to cleave the duplex of Xist and Tsix at the beginning of X-inactivation, to small ~30 nucleotide RNAs, which have been termed xiRNAs, These xiRNAs are believed to be involved in repressing Xist on the probable active X chromosome based upon studies. A study was conducted where normal endogenous Dicer levels were decreased to 5%, which led to an increase in Xist expression in undifferentiated cells, thus supporting the role of xiRNAs in Xist repression.[27] The role and mechanism of xiRNAs is still under examination and debate.[citation needed]

Tsix independent mechanisms

[edit]

Pluripotent cell transcriptional factors

[edit]

Pluripotent stem cells express transcription factors Nanog, Oct4 and Sox2 that seem to play a role in repressing Xist. In the absence of Tsix in pluripotent cells, Xist is repressed, where a mechanism has been proposed that these transcription factors cause splicing to occur at intron 1 at the binding site of these factors on the Xist gene, which inhibits Xist expression[24] A study was conducted where Nanog or Oct4 transcription factors were depleted in pluripotent cells, which resulted in the upregulation of Xist. From this study, it is proposed that Nanog and Oct4 are involved in the repression of Xist expression.[28]

Polycomb repressive complex

[edit]

Polycomb repressive complex 2 (PRC2) consist of a class of polycomb group proteins that are involved in catalyzing the trimethylation of histone H3 on lysine 27 (K27), which results in chromatin repression, and thus leads to transcriptional silencing. Xist RNA recruits polycomb complexes to the inactive X chromosome at the onset of XCI.[29] SUZ12 is a component of the PRC2 and contains a zinc finger domain. The zinc finger domain is believed to bind to the RNA molecule.[30] The PRC2 has been observed to repress Xist expression independent of the Tsix antisense transcript, although the definite mechanism is still not known.

Dosage compensation

[edit]

X-inactivation plays a key role in dosage compensation mechanisms that allow for equal expression of the X and autosomal chromosomes.[31] Different species have different dosage compensation methods, with all of the methods involving the regulation of an X chromosome from one of the either sexes.[31] Some methods involved in dosage compensation to inactivate one of the X chromosomes from one of the sexes are Tsix antisense gene, DNA methylation and DNA acetylation;[32] however, the definite mechanism of X-inactivation is still poorly understood. If one of the X chromosomes is not inactivated or is partially expressed, it could lead to over expression of the X chromosome and it could be lethal in some cases.

Turner syndrome is one example of where dosage compensation does not equally express the X chromosome, and in females one of the X chromosomes is missing or has abnormalities, which leads to physical abnormalities and also gonadal dysfunction in females due to the one missing or abnormal X chromosome. Turner syndrome is also referred to as a monosomy X condition.[33]

X-inactivation cycle

[edit]

Xist expression and X-inactivation change throughout embryonic development. In early embryogenesis, the oocyte and sperm do not express Xist and the X chromosome remains active. After fertilization, when the cells are in the 2 to 4 cell stage, Xist transcripts are expressed from paternal X chromosome(Xp) in every cell, causing that X chromosome to become imprinted and inactivated. Some cells develop into pluripotent cells (the inner cell mass) when the blastocyte forms. There, the imprint is removed, leading to the downregulation of Xist and thus reactivation of the inactive X chromosome. Recent data suggests that Xist activity is regulated by an anti-sense transcript.[34] The epiblast cells are then formed and they begin to be differentiated, and the Xist is upregulated from either of the two X chromosomes and at random in ICM, but the Xist is maintained in epiblast, an X is inactivated and the Xist allele is turned off in the active X chromosome. In maturing XX primordial germ cells, Xist is downregulated and X reactivation occurs once again.[35]

Disease linkage

[edit]

Mutations in the XIST promoter cause familial skewed X-inactivation.[5]

Interactions

[edit]

XIST has been shown to interact with BRCA1.[36][37]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

XIST

View on Grokipedia
from Grokipedia
XIST (X-inactive specific transcript) is a long non-coding RNA (lncRNA) gene located at Xq13.2 on the human X chromosome, encoding a nuclear-retained transcript of approximately 17 kb that is essential for X-chromosome inactivation (XCI) in female mammals. This process silences most genes on one of the two X chromosomes during early embryonic development to achieve dosage compensation with XY males, preventing overexpression of X-linked genes. The XIST RNA is expressed exclusively from the inactive X chromosome within the X-inactivation center (XIC), where it coats the chromosome in cis and recruits silencing complexes to initiate widespread epigenetic repression. The gene was first identified in 1991 by Brown et al. through screening a from , noting its unique expression solely from the inactive and its mapping to Xq13. Subsequent studies confirmed its structure, revealing a ~17–19 kb transcript with at least eight exons, extensive , tandem repetitive elements (such as the conserved repeats A–F), and no conserved , underscoring its non-protein-coding function. In mice, targeted disruption of the orthologous Xist gene demonstrated its necessity for XCI spreading, as mutants failed to form Barr bodies or silence X-linked genes properly. XIST upregulation occurs around the time of embryonic implantation, initially biallelically in some cells before resolving to monoallelic expression from the chosen inactive X, driven by factors like RNF12-mediated ubiquitination and repression of the antisense transcript TSIX. The RNA's coating mechanism involves interactions with polycomb repressive complex 2 (PRC2) for deposition, as well as factors like SHARP and HDAC3 for further compaction and , which begins ~2 days after upregulation. Dysregulation, such as promoter mutations (e.g., -43C>G), is linked to familial , potentially contributing to conditions like mental retardation syndromes in cases of defective XIST expression on structurally abnormal X chromosomes.

Gene and Transcript Structure

Genomic Location

The XIST gene is situated on the long arm of the X chromosome at cytogenetic band Xq13.2, with precise genomic coordinates spanning 73,820,656–73,852,714 (GRCh38.p14 primary assembly) on the complementary strand, encompassing approximately 32 kb of genomic DNA. This locus includes 9 exons and is part of the center (XIC), a critical regulatory region on the . The 's sequence lacks a significant (ORF), underscoring its classification as a (lncRNA) rather than a protein-coding , with no conserved coding potential identified across its exons. Within the XIC, the XIST locus is closely flanked by other key elements, notably the Tsix gene, which produces an antisense transcript originating approximately 15 kb downstream of XIST and extending across its locus in the opposite direction. This genomic arrangement facilitates reciprocal regulation between XIST and Tsix, contributing to the precise control of X-chromosome inactivation, though the primary focus here remains the positional context of XIST itself. Evolutionarily, exhibits conservation among eutherian mammals, with functional orthologs such as the murine Xist gene located at a syntenic position on the , sharing structural and sequence similarities that support its role in dosage compensation. However, the gene arose de novo in the eutherian lineage approximately 160-180 million years ago, with no detectable orthologs in non-eutherian mammals like marsupials (e.g., ) or monotremes (e.g., platypuses), reflecting its emergence alongside the of imprinted and random mechanisms in placental mammals. This conservation pattern highlights 's integral adaptation to eutherian .

Transcript Organization and Domains

The human XIST transcript is a measuring approximately 17-19 kb in length, derived from a primary transcript that undergoes processing to form a mature molecule consisting of eight s.90520-M) The first is notably large, spanning about 11 kb and encompassing much of the repetitive content, while subsequent s contribute to the overall structure without significant open reading frames, consistent with its non-coding nature. The transcript is modularly organized with several conserved repetitive domains that define its primary structure. The A-repeat region, located at the 5' end within 1, comprises approximately 8.5 tandem copies of a 26-nucleotide CG-rich motif separated by U-rich linkers. The C-repeat occupies a central position, primarily as a single motif in humans, facilitating structural integrity. Additional repeats, including B (GC-rich, adjacent to A), D (expanded in humans relative to other species), E (at the start of 7), and F (short motifs near the 3' end), are interspersed across the exons, contributing to the overall repetitive architecture with varying copy numbers and sequence compositions. Evolutionary analysis reveals variations in repeat composition across mammals, such as differences in copy number and length; for instance, the A-repeat features 7.5 copies in mice compared to 8.5 in humans, while the C-repeat is reduced to one copy in humans from multiple copies in , and the D-repeat shows expansion in . These modular elements exhibit secondary structure features, particularly in the A-region, where inter-repeat sequences form stable hairpin loops with AUCG tetraloops, as determined by and in-cell probing methods. Such structural motifs underscore the RNA's capacity for specific protein interactions that support its localization and function in X-chromosome inactivation.

Role in X-Chromosome Inactivation

Core Function

The core function of XIST, a , is to initiate and establish X-chromosome inactivation (XCI) in female mammals, ensuring dosage compensation by silencing the majority of genes on one of the two . This process equalizes X-linked between XX females and XY males, with XIST achieving random monoallelic expression such that only one remains active per cell. XIST transcripts are expressed exclusively from the future inactive (Xi) and coat it in cis, forming nuclear foci that spread along the territory to recruit silencing complexes. This coating leads to transcriptional repression of approximately 80-90% of X-linked genes, with the remaining genes either escaping inactivation or being subject to variable silencing across cell types and species. The mechanism of XIST-mediated silencing relies on its structural domains, particularly the conserved A-repeats located at the 5' end of the transcript. These repeats enable XIST RNA to form stable nuclear foci and recruit protein complexes, including SPEN and Polycomb repressive complexes, which deposit repressive histone marks like to enforce condensation and gene repression. Deletion or mutation of the A-repeats abolishes the silencing function, as demonstrated in transgenic models where XIST lacking this region fails to repress adjacent genes despite proper chromosomal localization. The spreading of XIST occurs linearly from the center, leveraging chromosome architecture to achieve chromosome-wide coverage within hours of upregulation. Experimental evidence from XIST knockout studies in mice confirms its essential role, as female embryos inheriting a paternal XIST deletion exhibit complete failure of imprinted XCI in extra-embryonic tissues, leading to embryonic lethality due to dosage imbalance. In random XCI contexts, conditional XIST knockouts in the epiblast result in defective dosage compensation, with persistent biallelic expression of X-linked genes and disrupted cellular differentiation. These findings underscore that without XIST, the Xi fails to form, and gene silencing does not initiate, highlighting its indispensable function in XCI establishment.

Integration with X-Inactivation Center

The X-inactivation center (XIC) comprises a cis-regulatory locus spanning approximately 1 Mb at Xq13.2 on the X chromosome, containing the gene alongside multiple noncoding and regulatory elements that coordinate the initiation and choice of (XCI). Note that the XIC is structurally expanded compared to the ortholog, with differences in regulatory elements. This region serves as the master control hub for dosage compensation in female mammals, ensuring monoallelic expression of X-linked genes by silencing one X chromosome. Central to XIST regulation within the XIC is the antisense transcript TSIX, which overlaps the XIST locus in an antisense orientation and actively represses XIST to prevent ectopic inactivation. TSIX exerts this repression through transcription interference, where the process of TSIX transcription physically blocks access to the XIST promoter, and promoter competition, wherein the convergent promoters of TSIX and XIST vie for limited transcriptional factors and resources. This antagonistic relationship ensures that XIST remains silent on the future active . In mice, additional XIC components include Xite, a cis-acting enhancer located upstream of Tsix that boosts Tsix transcription and thereby influences the probabilistic choice of which X chromosome undergoes inactivation, as demonstrated in mouse models. Repetitive elements such as the DXPas34 minisatellite, positioned downstream of Xist, also contribute to choice by modulating Tsix activity and promoting interchromosomal interactions during the decision phase of XCI. These elements collectively fine-tune the regulatory landscape to achieve random or imprinted XCI outcomes, though human equivalents differ. In the counting and choice phases of XCI, which occur early in embryonic development, the XIC evaluates X-chromosome dosage; subsequent downregulation of TSIX on the presumptive inactive X (Xi) relieves repression, leading to XIST upregulation and the onset of chromosome-wide coating and silencing. This dynamic interplay within the XIC ensures that only one X chromosome is inactivated per cell, with TSIX persisting on the active X to maintain its expression.

Regulatory Mechanisms

Promoter and Transcriptional Control

The promoter of the XIST gene is located at the 5' end of 1 and spans approximately 200 base pairs, encompassing key regulatory sequences that drive tissue-nonspecific transcription initiation. This minimal promoter region exhibits constitutive activity in various cell lines and transgenic models, with transcription factors such as SP1, YY1, and TBP binding to essential motifs to facilitate basal expression. Two conserved repetitive elements further modulate this activity: a set of 5'-end repeats that enhance promoter strength by threefold, and a 450-base-pair purine-pyrimidine tract located 25 kilobases upstream that suppresses it by about 70%, suggesting a role in fine-tuning XIST expression levels during development. In undifferentiated embryonic stem cells, the XIST promoter is repressed by pluripotency-associated transcription factors, including Nanog, Oct4 (also known as Pou5f1), and Sox2, which bind preferentially to a regulatory region within intron 1 approximately 4 kilobases downstream of the promoter. This binding correlates with low XIST transcription and prevents premature activation on both X chromosomes, maintaining dosage compensation equilibrium in pluripotent states; depletion of Nanog or Oct4 leads to rapid XIST upregulation and loss of factor occupancy at the locus. Antisense transcription from the overlapping Tsix gene provides an additional layer of control, as Tsix RNA synthesis extends across the XIST promoter on the active X chromosome (Xa), blocking promoter accessibility and chromatin remodeling that would otherwise permit XIST initiation. Truncation of Tsix transcription, but not the RNA product itself, results in ectopic XIST activation, underscoring the mechanistic importance of the transcriptional act in allele-specific repression. DNA methylation status at CpG islands within and flanking the promoter critically determines its activity, with hypermethylation on the Xa silencing transcription while hypomethylation on the future inactive (Xi) permits expression. This differential pattern is established early in development and persists somatically; treatment with demethylating agents like 5-azacytidine induces XIST expression from the normally silent Xa in hybrid cell models, confirming 's repressive role. Concurrently, Polycomb repressive complex 2 (PRC2), comprising core subunits and Eed, is recruited to the XIST promoter in naive embryonic stem cells, catalyzing trimethylation of at lysine 27 () to enforce repression independently of Tsix in certain contexts. This mark spreads across the promoter and upstream regions, and its disruption via PRC2 knockout leads to derepression and elevated XIST levels, highlighting PRC2's role in early, stable prior to differentiation cues that trigger promoter activation on the Xi.

Post-Transcriptional and Epigenetic Regulation

Post-transcriptional regulation of XIST RNA involves modifications that influence its stability and localization, ensuring precise control during X-chromosome inactivation. N6-methyladenosine (m6A) RNA methylation, catalyzed by the METTL3 methyltransferase, marks XIST transcripts and promotes their turnover through recruitment of the NEXT (Next complex) degradation pathway. This process limits XIST accumulation, and depletion of METTL3 enhances XIST stability, thereby accelerating X-chromosome silencing in differentiating cells. Although it has been proposed that XIST forms double-stranded RNA (dsRNA) structures with its antisense counterpart Tsix, which could trigger RNAi-like degradation mechanisms dependent on Dicer, studies have shown that X-chromosome inactivation proceeds normally in the absence of Dicer, indicating this pathway is dispensable for XIST repression and mutual exclusion with Tsix. Nonetheless, such dsRNA interactions may render XIST more susceptible to other nuclear degradation pathways, potentially fine-tuning its persistence during the establishment of inactivation. MicroRNAs further contribute to post-transcriptional fine-tuning of XIST expression, particularly in recent studies highlighting their in dosage compensation. For instance, miR-106a XIST, and its depletion leads to reduced XIST levels, influencing the efficiency of X-chromosome silencing in female cells. Such regulatory circuits allow for dynamic adjustment of XIST abundance in response to cellular contexts, preventing ectopic inactivation. Epigenetic regulation by XIST RNA is mediated through direct recruitment of chromatin-modifying complexes, facilitating the spread of silencing marks across the X chromosome. The repetitive A-repeat region of XIST binds Polycomb repressive complex 2 (PRC2), recruiting it to deposit histone H3 lysine 27 trimethylation (H3K27me3), a key repressive mark that initiates facultative heterochromatin formation. Independently, XIST interacts with DNMT3A to promote de novo DNA methylation at CpG islands, stabilizing long-term gene repression on the inactive X. Furthermore, XIST tethers the X chromosome to the nuclear lamina via binding to lamin B receptor (LBR), altering chromatin architecture and enhancing the compartmentalization of silenced domains. Recent advances (2023–2025) have elucidated how XIST leverages formation through liquid–liquid (LLPS) to optimize epigenetic spreading. XIST , in complex with proteins like hnRNPK, forms phase-separated condensates that concentrate silencing factors, enabling efficient cis-propagation along the chromosome while limiting trans-diffusion. These condensates integrate m6A-modified XIST with epigenetic recruiters like PRC2, amplifying deposition and association for robust inactivation.

Dynamics and Maintenance

X-Inactivation Cycle

X-chromosome inactivation (XCI) in female mammals begins during early embryonic development, with expression playing a central role in eutherian species. In mice, initiation occurs in pre-implantation embryos at the 2- to 4-cell stage, where is upregulated exclusively from the paternal , leading to imprinted XCI in extra-embryonic tissues. This paternal bias is driven by maternal repression of the allele via marks established during , ensuring monoallelic expression from the unmarked paternal allele. In contrast, human pre-implantation embryos exhibit biallelic upregulation shortly after fertilization, but this does not trigger XCI; instead, random XCI initiates post-implantation in the epiblast lineage. The X-inactivation cycle encompasses distinct temporal phases. Prior to inactivation, XIST expression remains low across both X chromosomes in early embryos, maintaining biallelic activity. Upregulation then occurs stochastically on the future inactive X (Xi) during random XCI or paternally in imprinted XCI, with XIST RNA accumulating and coating the Xi in cis. This coating spreads across the chromosome in a two-step process—first targeting gene-rich regions, then gene-poor domains—over approximately 4-6 hours in model systems mimicking embryonic conditions, recruiting silencing factors like Polycomb complexes to initiate gene repression. By gastrulation, XIST-mediated coating establishes irreversible silencing of the Xi, stabilizing dosage compensation. Species differences highlight evolutionary variations in XCI timing and mechanism. Marsupials exhibit imprinted XCI of the paternal X from early cleavage stages, but lack XIST; instead, they utilize a distinct lncRNA, RSX, for Xi coating. Eutherians, including and , rely on XIST for both imprinted (in mouse extra-embryonic tissues) and random XCI (predominant in soma and mouse epiblast), with random choice ensuring equitable inactivation of either parental X. This somatic persistence of XIST expression maintains the Xi throughout development.

Somatic Expression and Stability

In differentiated somatic cells, XIST expression persists throughout a female's lifespan to maintain the inactive (Xi), ensuring stable despite attempts to reactivate X-linked genes. This lifelong duty is facilitated by XIST coating the Xi and recruiting RNA-binding proteins such as PTBP1, MATR3, TDP-43, and CELF1 to its E-repeat region, which form supramolecular assemblies that reinforce epigenetic modifications like and sustain the Xi's condensed structure. Even when XIST is experimentally depleted in human somatic cells, such as B lymphocytes, approximately 25% of Xi genes show upregulation, particularly escapee genes with low , highlighting XIST's essential role in countering reactivation pressures while redundant mechanisms like deacetylation provide partial compensation. Recent 2025 studies on somatic XIST deletions in human retinal pigment epithelial cells (hTERT RPE-1) demonstrate that partial loss, such as deletions in the A, F, or E repeats, leads to variable reactivation of X-linked genes without causing widespread dosage imbalance. Complete XIST loss results in an average 20% increase in expression of escape genes like USP9X and MED14, accompanied by reduced repressive marks such as H3K27me3 and H2AK119ub, yet overall Xi silencing remains largely intact due to combinatorial epigenetic pathways. These findings indicate that XIST's modular domains contribute differentially to suppression, with the A repeat being critical for broad heterochromatin maintenance, and underscore the tolerance of somatic cells to partial XIST perturbations without catastrophic X-expression imbalances. XIST RNA exhibits high stability in differentiated somatic states, resisting degradation through interactions with stabilizing proteins at the E repeat that uncouple localization from turnover, allowing persistent Xi coating. This resistance increases as X-chromosome inactivation (XCI) progresses, with XIST extending in mature Barr bodies compared to early stages. Cellular stress, such as T-cell activation, can modulate XIST-dependent maintenance via signaling, which influences Xi organization without altering XIST levels. In human naive pluripotent stem cells, 2024 findings show that XIST not only dampens X-linked to achieve dosage compensation but also targets autosomal loci, reducing transcription of over 1,500 genes in a SPEN-dependent manner via repressive modifications like H3K27me3. This broader regulatory role in naive states contrasts with somatic persistence, where XIST primarily sustains Xi integrity, and involves XIST spreading to ~724 conserved autosomal peaks, leading to male-biased expression patterns in affected genes such as SPON1.

Clinical and Therapeutic Implications

Disease Associations

Mutations in the XIST gene, particularly in its promoter region such as the -43C>G transversion, are associated with familial skewed X-chromosome inactivation, where the mutated X chromosome is preferentially inactivated. This skewing can lead to the manifestation of X-linked disorders in females by resulting in a higher proportion of cells expressing the mutant allele on the active X chromosome. For instance, in Rett syndrome caused by MECP2 mutations, skewed X-inactivation has been observed to influence disease severity, with non-random patterns correlating with phenotypic variability in affected individuals and carriers. Similarly, in X-linked immunodeficiencies like chronic granulomatous disease, extreme skewing of X-inactivation can cause disease onset in female carriers by favoring expression of the defective gene. Aberrant XIST expression is implicated in various cancers, particularly in females where it disrupts X-linked . In , loss of XIST expression is frequently observed and correlates with poor , increased tumor aggressiveness, and higher risk of , as it leads to reactivation of silenced X-linked genes and promotes stem cell-like properties in tumor cells. This dysregulation contributes to altered cellular proliferation and invasion, with studies showing that XIST downregulation upregulates pathways like AKT signaling, exacerbating . In autoimmune diseases, particularly systemic lupus erythematosus (SLE), failed maintenance of XIST-mediated X-chromosome inactivation results in incomplete silencing of the inactive , leading to overexpression of immune-related X-linked genes. This escape from inactivation is more pronounced in T cells from female SLE patients, contributing to the female bias in disease prevalence and heightened through dysregulated immune responses. Recent studies from 2023 to 2025 have linked somatic loss of to disorders, where heterogeneous patterns arise post-developmentally, influencing variable expressivity of X-linked traits. For example, somatic deletions in fibroblasts cause upregulation of select X-linked genes and epigenetic instability, potentially underlying phenotypes in developmental or tissue-specific disorders. Such events highlight how acquired dysregulation can contribute to phenotypic variability in X-linked conditions beyond mutations.

Therapeutic Potential

Recent studies have demonstrated the potential of ectopic XIST expression to silence extra chromosomes in models, particularly for ( 21). In human (iPSC) models of , insertion of an XIST into one of the three copies led to comprehensive silencing of that chromosome, reducing trisomic by approximately 33% as measured by RNA sequencing, with no significant escape genes observed. This approach corrected cellular phenotypes associated with , such as defects in hematopoiesis and , by normalizing gene dosage and restoring pathways like Notch signaling. Inducible XIST systems in these models further highlight translational promise for therapies using patient-derived stem cells. Targeting phase-separated XIST condensates offers a strategy for reactivating the inactive X chromosome (Xi) in neurodevelopmental disorders. XIST RNA forms condensates via liquid-liquid phase separation that recruit silencing factors like PRC2 and SPEN, maintaining Xi repression; disrupting these structures could reverse inactivation of disease-linked genes. In models of Rett syndrome, an X-linked neurodevelopmental disorder caused by MECP2 mutations, pharmacological reactivation of the Xi has restored MECP2 expression in cerebral cortical neurons, improving neuronal function. Approaches include small molecules that bind XIST's A-repeat to inhibit PRC2 and SPEN interactions, preventing histone methylation and gene silencing, as well as RNA aptamers targeting SPEN's intrinsically disordered regions to block phase separation. Pharmacological modulation of XIST through inhibitors of m6A machinery or PRC2 provides avenues for fine-tuning its activity in cancer and imprinting defects. Inhibition of the m6A complex METTL3/14 reduces XIST , weakening condensate formation and potentially derepressing Xi genes in imprinting-related disorders where m6A guides . In cancer contexts, PRC2 inhibitors disrupt XIST-mediated silencing interactions, offering a means to modulate oncogenic or tumor-suppressive roles of XIST, as seen in preclinical models where such compounds enhance anti-tumor effects by altering metabolism. PROTACs targeting condensate components like SPEN further enable selective degradation, providing precision in these applications. Despite these advances, challenges in XIST-based therapies include off-target effects, such as unintended reactivation of multiple genes (over 10 in some XIST depletion models), which could lead to dosage imbalances. Delivery remains a barrier, particularly for neural tissues in neurodevelopmental disorders, where crossing the blood-brain barrier requires repeated administration and optimized vectors, limited by the large size of the (~14 kb). Species-specific differences, such as variations in versus XIST functionality, complicate translation to trials, necessitating further validation of minigene constructs and long-term safety assessments.

Molecular Interactions

Protein and RNA Partners

XIST RNA, a long non-coding RNA essential for X-chromosome inactivation, interacts directly with several protein partners that facilitate its localization, stability, and repressive functions. The Polycomb repressive complex 2 (PRC2), particularly through its EZH2 catalytic subunit, binds to the A-repeats of XIST, promoting deposition along the . This interaction is mediated by high-affinity RNA binding, with enhancing PRC2 recruitment to RepA/XIST RNA . Similarly, the SPEN (also known as SHARP) directly associates with the A-repeats via its RRM domains, recruiting the SMRT/HDAC3 corepressor complex to initiate local . SPEN's binding affinity is high enough that four A-repeat units suffice for robust interaction, underscoring the modular nature of XIST's silencing domains. Additionally, heterogeneous nuclear ribonucleoprotein U (hnRNP U) binds XIST to ensure its nuclear retention and chromosomal localization; depletion of hnRNP U causes XIST to detach from the inactive (Xi) and disperse into the nucleoplasm, disrupting accumulation. Beyond these core proteins, XIST engages RNA partners that influence its structure and localization. The antisense transcript Tsix forms RNA duplexes with XIST , particularly overlapping in exon 4, which may destabilize XIST or mask its functional domains to prevent ectopic inactivation. This duplex formation is a key regulatory mechanism during choice, processed potentially by to inhibit XIST accumulation. The lncRNA Firre, expressed from the active , contributes to looping on the Xi; its interaction with XIST helps maintain trans-chromosomal contacts, such as the Dxz4-Firre superloop, which supports epigenetic stability. Recent studies from 2023–2025 highlight additional interactors modulating XIST dynamics. The nuclear exosome targeting (NEXT) complex, including ZFC3H1, binds m6A-modified sites on XIST to promote its turnover, ensuring timely degradation during ; disruption of NEXT or m6A writer METTL3 prolongs XIST and accelerates silencing. MicroRNAs also target the 3' region of XIST, with examples like miR-149-3p binding to sequences analogous to a 3' UTR, reducing XIST levels and alleviating its oncogenic effects in cancers such as ovarian carcinoma. Specific binding motifs within XIST's repeat regions dictate partner affinity. The A-repeats contain AUCG tetraloop folds that preferentially recruit SPEN and PRC2, while the B-repeat's C-rich motifs engage hnRNPK (which aids PRC1 ) with sequence-specificity enhanced by flanking U-rich spacers. The D-repeat, comprising 14 units of a 290-nucleotide motif, shows periodical binding patterns for hnRNP U and hnRNPK, as revealed by eCLIP mapping, illustrating how tandem repeats modularize protein interactions across the ~17 kb XIST transcript. These motifs ensure selective, high-affinity binding, with environmental factors like cellular context further modulating accessibility.

Functional Networks

XIST plays a central role in the dosage compensation network by orchestrating epigenetic modifications that balance X-linked between sexes. Through its coating of the , XIST recruits Polycomb repressive complex 2 (PRC2), leading to the deposition of lysine 27 trimethylation (), which propagates silencing across the territory. This enrichment integrates XIST into broader epigenomic cascades, where it cooperates with to maintain long-term stability; for instance, de novo methyltransferases DNMT3A and DNMT3B reinforce promoter silencing on the inactive X, preventing reactivation. These interconnected modifications ensure dosage compensation while linking XIST to global pathways that influence autosomal gene regulation indirectly. In the context of stem cell pluripotency, XIST interacts with core transcriptional circuits involving Oct4 and Nanog to modulate dosage compensation during early development. In human pluripotent stem cells (hPSCs), XIST expression dampens X-linked genes and extends regulatory influence to autosomes in trans, particularly in naïve states where it binds non-X loci to alter sex-biased expression patterns; depletion of Nanog or Oct4 can trigger ectopic XIST upregulation, disrupting pluripotency maintenance. Recent analyses of human induced pluripotent stem cells (iPSCs) from 2024 reveal that XIST erosion leads to dose-dependent changes in autosomal gene expression, enriching for male-biased expression and highlighting XIST's role in integrating XCI with pluripotency networks to preserve cellular identity. Evolutionarily, XIST is conserved within the eutherian X-inactivation center (XIC), where its functional domains (A-F) exhibit varying sequence preservation across mammals, enabling coordinated regulation of XCI. Originating post-divergence from marsupials, XIST's syntenic XIC locus, including regulators like Tsix and Jpx, maintains structural integrity in eutherians, though with species-specific variations such as truncated TSIX in humans. This conservation underpins sex-biased , as incomplete XCI escape (affecting 10-20% of genes in most eutherians) results in female-specific dosage imbalances that influence traits like and . Recent 2025 studies have integrated into networks, revealing its biophysical contributions to territory organization. , via its Repeat B motifs, drives liquid-liquid (LLPS) with proteins like HNRNPK, forming condensates that encapsulate and soften the for cis-restricted spreading. These phase-separated assemblies concentrate silencing factors, restructuring compartments and territories to facilitate stable XCI, with mutations disrupting LLPS impairing polycomb recruitment and . This mechanism positions at the nexus of biomolecular condensates and higher-order genome architecture in dosage compensation.

References

  1. https://www.ncbi.nlm.nih.gov/gene/7503
  2. https://omim.org/entry/314670
  3. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-015-0733-y
  4. https://www.nature.com/articles/s41467-021-23643-6
  5. https://www.sciencedirect.com/science/article/pii/009286749290520M
  6. https://pubmed.ncbi.nlm.nih.gov/10723727/
  7. https://www.nature.com/articles/ng0499_400
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC1383731/
  9. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002521
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC10077506/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC12101419/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC3734131/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8786293/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5742192/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC3198591/
  16. https://www.cell.com/fulltext/S0092-8674(00)80071-9
  17. https://jbiol.biomedcentral.com/articles/10.1186/jbiol95
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10742877/
  19. https://pubmed.ncbi.nlm.nih.gov/11780141/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC7362899/
  21. https://www.sciencedirect.com/science/article/pii/S2211124723006976
  22. https://genesdev.cshlp.org/content/11/2/156
  23. https://pubmed.ncbi.nlm.nih.gov/27542829/
  24. https://pubmed.ncbi.nlm.nih.gov/8401491/
  25. https://www.sciencedirect.com/science/article/pii/S0092867411006684
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC1274371/
  27. https://www.pnas.org/doi/10.1073/pnas.171243598
  28. https://www.sciencedirect.com/science/article/pii/S1534580705001851
  29. https://www.sciencedirect.com/science/article/pii/S1097276503000637
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC84967/
  31. https://www.sciencedirect.com/science/article/pii/S1534580706005545
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC5064214/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC146792/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC100014/
  35. https://academic.oup.com/nar/article/26/12/2935/2385820
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4609750/
  37. https://www.nature.com/articles/s41594-025-01663-w
  38. https://www.pnas.org/doi/10.1073/pnas.0812210106
  39. https://journals.asm.org/doi/10.1128/mmbr.68.3.432-452.2004
  40. https://www.nature.com/articles/s41467-025-61092-7
  41. https://www.embopress.org/doi/10.15252/embr.201948019
  42. https://www.sciencedirect.com/science/article/pii/S2352304222001052
  43. https://pubmed.ncbi.nlm.nih.gov/27492478/
  44. https://www.cell.com/cell/fulltext/S0092-8674%2824%2901417-X
  45. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-025-03666-8
  46. https://doi.org/10.1038/s41556-023-01266-x
  47. https://doi.org/10.1242/dev.127.19.4137
  48. https://doi.org/10.1038/nature12719
  49. https://doi.org/10.1038/nrg2987
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9472561/
  51. https://pubmed.ncbi.nlm.nih.gov/41128597/
  52. https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddaf160/8300178
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC2133021/
  54. https://www.science.org/doi/10.1126/science.abe7500
  55. https://www.science.org/doi/10.1126/sciadv.ads8169
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC12088372/
  57. https://www.cell.com/cell/fulltext/S0092-8674(23)01319-3
  58. https://www.nature.com/articles/s41594-024-01325-3
  59. https://pubmed.ncbi.nlm.nih.gov/9354806/
  60. https://www.nature.com/articles/5201682
  61. https://pubmed.ncbi.nlm.nih.gov/31522453/
  62. https://www.oncotarget.com/article/9673/text/
  63. https://www.cell.com/cell/fulltext/S0092-8674(22)00532-3
  64. https://insight.jci.org/articles/view/126751
  65. https://www.mdpi.com/2311-553X/11/5/67
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC11294271/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4379047/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC10870365/
  69. https://www.sciencedirect.com/science/article/pii/S1534580710003813
  70. https://www.nature.com/articles/s41467-025-59496-6
  71. https://www.nature.com/articles/s41467-018-07446-w
  72. https://www.nature.com/articles/s41419-020-03358-0
  73. https://www.nature.com/articles/s41467-020-20040-3
  74. https://www.biorxiv.org/content/10.1101/2023.10.04.560814v2.full-text
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6249047/
  76. https://www.sciencedirect.com/science/article/pii/S0092867400816566
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC3251695/
  78. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-024-03286-8
  79. https://www.embopress.org/doi/10.1038/s44319-025-00499-1
  80. https://www.cell.com/cell/fulltext/S0092-8674(24)01417-X
Add your contribution
Related Hubs
User Avatar
No comments yet.